Revenue - Allocation of Performance Obligation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Norgine Agreement
Collaboration License And Funding Arrangements [Line Items]
Remaining performance obligation	$ 29,856
Revenue from collaborative arrangement, excluding revenue from contract with customer	239	$ 27,865
Norgine Agreement, License
Collaboration License And Funding Arrangements [Line Items]
Remaining performance obligation	27,639
Revenue from collaborative arrangement, excluding revenue from contract with customer	0	27,639
Norgine Agreement, R&D - WHIM
Collaboration License And Funding Arrangements [Line Items]
Remaining performance obligation	312
Revenue from collaborative arrangement, excluding revenue from contract with customer	0	17
Norgine Agreement, R&D - CN
Collaboration License And Funding Arrangements [Line Items]
Remaining performance obligation	1,724
Revenue from collaborative arrangement, excluding revenue from contract with customer	58	209
Norgine Agreement, Drug Product Supply
Collaboration License And Funding Arrangements [Line Items]
Remaining performance obligation	181
Revenue from collaborative arrangement, excluding revenue from contract with customer	$ 181	$ 0